Kim Kelderman

The company's R&D Systems brand is widely regarded as the gold standard for recombinant proteins — the purified biological molecules that researchers use to study disease mechanisms, develop drugs, and create diagnostic tests. Bio-Techne operates through two segments: Protein Sciences (recombinant proteins, antibodies, immunoassays, and related reagents) and Diagnostics & Genomics (molecular diagnostics, spatial biology tools through the ACD/RNAscope platform, and clinical diagnostics). The company's products are essential consumables in the research workflow — once a lab validates its protocols using Bio-Techne's reagents, switching costs are high because changing suppliers risks experimental reproducibility. The spatial biology platform (ACD/RNAscope and recently acquired Lunaphore) represents Bio-Techne's growth frontier, enabling researchers to visualize gene and protein expression within intact tissue sections. Key stock drivers include biopharma R&D spending, academic research funding, spatial biology instrument and consumable adoption, protein sciences growth, diagnostic revenue contribution, and the overall health of the life sciences tools sector.